Coherus Biosciences Inc (OQ:CHRS)

Sector:  Healthcare Industry:  Biotechnology & Medical Research
See Regulatory Filings on SEC
Company Contact
Address: 333 Twin Dolphin Dr Ste 600
REDWOOD CITY CA 94065-1442
Tel: N/A
IR: See website
Key People
Dennis M. Lanfear
Chairman of the Board, President, Chief Executive Officer
Jean-Frederic Viret
Chief Financial Officer
Vincent R. Anicetti
Chief Operating Officer
Peter K. Watler
Chief Technology Officer
Vladimir Vexler
Chief Scientific Officer
Barbara K. Finck
Chief Medical Officer
Thomas Fitzpatrick
Chief Legal Officer
Darlene P. Horton
Chief Medical and Regulatory Affairs Officer
Business Overview
Coherus BioSciences, Inc. is a late-stage clinical biologics platform company. The Company is engaged in the business of developing and commercializing biosimilar products. The Company's business is organized around therapeutic franchises, including Oncology biosimilar candidates pegfilgrastim (Neulasta) and bevacizumab (Avastin); Immunology (Anti-TNF) biosimilar candidates etanercept (Enbrel) and adalimumab (Humira); Ophthalmology biosimilar candidate ranibizumab (Lucentis), and Multiple sclerosis small molecule therapeutic candidate, CHS-131. The Company's product candidate pipeline includes CHS-1701, CHS-5217, CHS-0214, CHS-1420 and CHS-3351. Its CHS-1701 is a Granulocyte colony-stimulating factor (G-CSF) product candidate. Its Bevacizumab is a recombinant humanized monoclonal antibody that blocks angiogenesis by inhibiting vascular endothelial growth factor A (VEGF-A). Its Etanercept (Enbrel) is the reference product for CHS-0214.
Financial Overview
For the nine months ended 30 September 2019, Coherus Biosciences Inc revenues increased from $0K to $232.2M. Net income totaled $50.6M vs. loss of $146.7M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net Income reflects Research and development decrease of 30% to $48.8M (expense), Related party expense decrease of 97% to $50K (expense).
Employees: 272 as of Sep 30, 2019
Reporting Currency: U.S. Dollars
Enterprise value: $1,400M as of Sep 30, 2019
Annual revenue (TTM): $232.22M as of Sep 30, 2019
EBITDA (TTM): $5.05M as of Sep 30, 2019
Net annual income (TTM): -$11.99M as of Sep 30, 2019
Free cash flow (TTM): -$38.37M as of Sep 30, 2019
Net Debt Last Fiscal Year: $7.28M as of Sep 30, 2019
Shares outstanding: 70,129,340 as of Oct 31, 2019
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization